10,389 reports of this reaction
3.7% of all SPIRONOLACTONE reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for SPIRONOLACTONE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 10,389 FDA adverse event reports linking SPIRONOLACTONE to DYSPNOEA. This represents approximately 3.7% of all 279,694 adverse event reports for this drug.
SPIRONOLACTONE has an overall safety score of 85 out of 100. Patients taking SPIRONOLACTONE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among SPIRONOLACTONE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for SPIRONOLACTONE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 10,389 FDA reports for SPIRONOLACTONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.7% of all adverse event reports for SPIRONOLACTONE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking SPIRONOLACTONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.